Project Grant R01HL187284
Award Date 8/19/26
Completion Date 4/30/30
Dollars Obligated $758K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The University of Texas Southwestern Medical Center $246,000 on August 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate sex-specific differences in subclinical cardiovascular disease phenotypes and their relationship to psychosocial stress. The recipient will develop expertise in subclinical atherosclerosis measures and cardiovascular imaging phenotypes while examining whether chronic psychosocial...
- The National Heart, Lung, and Blood Institute awarded the University of South Carolina $100,228 on December 31, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on the mechanistic pathways linking hypertension, autoimmunity, and chronic psychological stress. The research tests whether chronic stress exacerbates immune system activation and hypertension in a female hypertensive mouse model of systemic lupus erythematosus (NZBWF1). The investigator's...
- The National Heart, Lung, and Blood Institute awarded Texas A&M University System Health Science Center $761,981 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Project Grant R01HL182020). The award funds research characterizing the function and signaling mechanisms of Regulator of G-Protein Signaling (RGS) proteins in platelet biology, with specific focus on RGS10, RGS16, and RGS18. The research addresses mechanistic aspects of RGS protein regulatory...
- The National Heart, Lung, and Blood Institute awarded Texas A&M Engineering Experiment Station $706,159 on August 19, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a smart wearable continuous cuffless blood pressure, cardiac, and respiratory monitoring system agnostic to skin tone. The recipient will design and build an innovative wearable device integrating multiple non-invasive physiological sensors on the wrist to provide health-grade continuous...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $865,711 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate beta-2 adrenergic receptor polymorphic variants as an endotype of salt-sensitive hypertension. The recipient will conduct translational research in humans and mice carrying either the risk (ARG16ARG/GLN27GLN) or non-risk (GLY16GLY/GLU27GLU) beta-2 adrenergic receptor diplotypes to distinguish between...
- The National Heart, Lung, and Blood Institute awarded The University of Texas Southwestern Medical Center $608,173 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the stretch-activated PIEZO1 channel in heart failure-associated atrial fibrillation. The research comprises three aims: testing the hypothesis that atrial stretch-induced PIEZO1 activation contributes to pathological atrial remodeling and atrial fibrillation predisposition...
- The National Heart, Lung, and Blood Institute awarded Louisiana State University Health Sciences Center-Shreveport $111,111 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms linking endoplasmic reticulum stress, lipid accumulation, and vascular inflammation in atherosclerosis. The research defines how the NCK1 adaptor protein integrates mechanical and metabolic stress to drive endothelial dysfunction. Aim 1 investigates how NCK1...
- Federal Grant Award Summary The University of Texas Health Science Center at Houston received a $234,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 15, 2025 through July 31, 2027. The research will investigate the force transduction mechanisms of leukocyte function-associated antigen-1 (LFA-1), a critical CD18 integrin that mediates immune cell adhesion, migration, and...
- Federal Grant Award Summary Northern Illinois University received a $380,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025 through August 31, 2028. This R15 award supports fundamental research investigating neural mechanisms underlying emotion regulation, stress resilience, and cardiovascular health outcomes in the context of adolescent social stress. The project employs...
- The National Heart, Lung, and Blood Institute awarded Baylor College of Medicine $643,349 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 17, 2026, to investigate the role of gasdermin D (GSDMD) inhibition in reducing inflammation-related atrial fibrillation risk associated with clonal hematopoiesis and aging. The research employs bone marrow transplantation, deep cardiac phenotyping, single-cell transcriptomics, and genetic analyses to elucidate how clonal...